STM:第一代广谱性流感疫苗有望开发

2012-08-22 ZinFingerNase 生物谷

在寻求开发一种广谱性流感疫苗---它能够诱导广泛性的中和抗体产生,能够保护免受大多数或全部流感病毒毒株感染---过程中,科学家们面临着一个严肃的问题:预存免疫性(pre-existing immunity)是由之前感染过的流感病毒导致的吗?或者疫苗阻止广泛中和的抗体产生吗?如果是这样的话,广谱流感疫苗可能在非常年轻的儿童体内作用最佳,这是因为他们只是有限地接触流感病毒或疫苗。 如今,在利用小鼠和

在寻求开发一种广谱性流感疫苗---它能够诱导广泛性的中和抗体产生,能够保护免受大多数或全部流感病毒毒株感染---过程中,科学家们面临着一个严肃的问题:预存免疫性(pre-existing immunity)是由之前感染过的流感病毒导致的吗?或者疫苗阻止广泛中和的抗体产生吗?如果是这样的话,广谱流感疫苗可能在非常年轻的儿童体内作用最佳,这是因为他们只是有限地接触流感病毒或疫苗。

如今,在利用小鼠和雪貂开展的研究中,来自美国国家过敏症与传染病研究所疫苗研究中心的研究人员证实广泛性中和的流感抗体确实能够经初次免疫-加强免疫疫苗(prime-boost vaccine)疗法诱发而产生,甚至即便是这些动物对流感病毒产生预存免疫性,也是如此。

这种疫苗是由引发初次免疫的DNA疫苗和随后一种用于加强免疫的灭活的季节性疫苗组成的。不论预存免疫性是由于宿主感染过流感病毒还是由于接种标准的季节性流感疫苗而产生的,这并不重要。因接受初次免疫-加强免疫疫苗接种而对流感病毒产生免疫性的雪貂免受不匹配的流感病毒毒株的攻击。

根据研究人员的说法,如果同样的效应也能在人体中发现的话,那么它可能给所有年龄的人们提供持续长期的流感保护。

几项研究第一代广谱流感疫苗产生广泛性中和抗体能力的临床试验正在美国国家过敏症与传染病研究所疫苗研究中心进行或者计划中。

本文编译自Study suggests potential hurdle to universal flu vaccine development may be overcome

doi: 10.1126/scitranslmed.3004273
PMC:
PMID:

Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure

The immune system responds to influenza infection by producing neutralizing antibodies to the viral surface protein, hemagglutinin (HA), which regularly changes its antigenic structure. Antibodies that target the highly conserved stem region of HA neutralize diverse influenza viruses and can be elicited through vaccination in animals and humans. Efforts to develop universal influenza vaccines have focused on strategies to elicit such antibodies; however, the concern has been raised that previous influenza immunity may abrogate the induction of such broadly protective antibodies. We show here that prime-boost immunization can induce broadly neutralizing antibody responses in influenza-immune mice and ferrets that were previously infected or vaccinated. HA stem–directed antibodies were elicited in mice primed with a DNA vaccine and boosted with inactivated vaccine from H1N1 A/New Caledonia/20/1999 (1999 NC) HA regardless of preexposure. Similarly, gene-based vaccination with replication-defective adenovirus 28 (rAd28) and 5 (rAd5) vectors encoding 1999 NC HA elicited stem-directed neutralizing antibodies and conferred protection against unmatched 1934 and 2007 H1N1 virus challenge in influenza-immune ferrets. Indeed, previous exposure to certain strains could enhance immunogenicity: The strongest HA stem–directed immune response was observed in ferrets previously infected with a divergent 1934 H1N1 virus. These findings suggest that broadly neutralizing antibodies against the conserved stem region of HA can be elicited through vaccination despite previous influenza exposure, which supports the feasibility of developing stem-directed universal influenza vaccines for humans.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1677868, encodeId=874d16e7868ee, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sat Aug 25 17:00:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081031, encodeId=78a1208103134, content=<a href='/topic/show?id=0ca2e57393d' target=_blank style='color:#2F92EE;'>#第一代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75739, encryptionId=0ca2e57393d, topicName=第一代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941121, encodeId=a808194112171, content=<a href='/topic/show?id=6977491908f' target=_blank style='color:#2F92EE;'>#广谱性流感疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49190, encryptionId=6977491908f, topicName=广谱性流感疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Mon Mar 25 03:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=)]
    2012-08-25 gdsun
  2. [GetPortalCommentsPageByObjectIdResponse(id=1677868, encodeId=874d16e7868ee, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sat Aug 25 17:00:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081031, encodeId=78a1208103134, content=<a href='/topic/show?id=0ca2e57393d' target=_blank style='color:#2F92EE;'>#第一代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75739, encryptionId=0ca2e57393d, topicName=第一代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941121, encodeId=a808194112171, content=<a href='/topic/show?id=6977491908f' target=_blank style='color:#2F92EE;'>#广谱性流感疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49190, encryptionId=6977491908f, topicName=广谱性流感疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Mon Mar 25 03:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=)]
    2013-03-18 pcw106
  3. [GetPortalCommentsPageByObjectIdResponse(id=1677868, encodeId=874d16e7868ee, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Sat Aug 25 17:00:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081031, encodeId=78a1208103134, content=<a href='/topic/show?id=0ca2e57393d' target=_blank style='color:#2F92EE;'>#第一代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75739, encryptionId=0ca2e57393d, topicName=第一代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Mar 18 21:00:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941121, encodeId=a808194112171, content=<a href='/topic/show?id=6977491908f' target=_blank style='color:#2F92EE;'>#广谱性流感疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49190, encryptionId=6977491908f, topicName=广谱性流感疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Mon Mar 25 03:00:00 CST 2013, time=2013-03-25, status=1, ipAttribution=)]